Homepage Top Section2

The trial has not achieved its primary endpoint of OS with Opdivo (nivolumab) 1mg/kg in combination with Yervoy (ipilimumab) 3mg/kg against placebo as a maintenance therapy for patients

The approval of Pelmegis follows the recommendation of the Medicinal Products for Human Use (CHMP), which was based on regulatory submission of significant biosimilarity data from analytical, biofunctional

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, which is under phase 3 development by GSK to treat anemia associated with chronic kidney disease (CKD). Inhibition of

Daurismo is claimed to be the first and only FDA-approved Hedgehog pathway inhibitor for AML. Daurismo, which is taken in combination with low-dose cytarabine (LDAC), has not been

In the trail, the clinical-stage biotechnology company will evaluate uproleselan in combination with MEC (mitoxantrone, etoposide and ara-C) or in combination with FAI (fludarabine, ara-C and idarubicin). Both

As part of the collaboration worth $300m, Boehringer and Epizyme will involve in the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed

The FDA designation for the Tecentriq chemo combination is for TNBC patients whose condition is unresectable locally advanced or metastatic and whose disease expresses the PD-L1 protein, as

The analysis, which is part of the 3b Expedition-8 study, assessed the safety and efficacy of Mavyret in treatment-naïve chronic hepatitis C virus (HCV) patients with compensated cirrhosis

Mirum Pharmaceuticals is focused on the development of an approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions. Maralixibat is under development for